In a large sample of US adults with T2D and established ASCVD, treatment with OW GLP-1 RAs was associated with decreased risk of ischemic stroke and MI and fewer ASCVD-related and all-cause HCRU and medical costs compared with DPP-4is. Here, GLP1R is linked to type 2 diabetes mellitus.